Compare ASML Holding NV (ASML) vs Biogen Inc (BIIB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ASML Holding NV vs Biogen Inc — how do they compare? ASML Holding NV trades at $1,815 (market cap $689.17B), while Biogen Inc trades at $208.9 (market cap $30.13B). The key difference: ASML Holding NV is far larger — about 22.9× Biogen Inc's market cap, and ASML Holding NV pays a 0.5% dividend while Biogen Inc pays none. Which is the better fit depends on your goals.
| ASML | BIIB | |
|---|---|---|
Market Cap | $689.17B | $30.13B |
Sector | Technology | Health |
52-Week High | $1.99K | $216.63 |
52-Week Low | $725.85 | $128.93 |
Enterprise Value | $682.70B | $37.20B |
Dividend Yield | 0.5% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ASML trades at $1,819.44, up 4.96% today, with a bullish technical signal from moving averages. The stock shows strong fundamentals with 2025 revenue of $32.67B and net income of $9.61B, though valuation ratios like a P/E of 61.28 are elevated. Recent earnings beat expectations in Q1 and Q2 2026, and analyst consensus is a Buy with a $2,390 price target. News highlights AI-driven demand for its semiconductor equipment.
Outlook is positive due to AI lithography demand and High-NA EUV expansion, but risks include high valuation sensitivity and geopolitical threats from Chinese self-sufficiency efforts. The stock offers growth potential with 31% upside to the consensus target, balanced by execution and competitive risks.
Biogen (BIIB) trades at $206.48, down 0.31% on the day, with a bullish technical signal supported by moving averages. The company reported Q2 2026 EPS of $3.60, beating estimates of $2.94, and raised full-year guidance, driven by growth in Alzheimer's and rare disease portfolios. Recent acquisitions like RayThera and Apellis bolster its pipeline. Revenue for 2025 was $9.89 billion with a net income margin of 13.07%, though margins have fluctuated year-over-year.
Outlook remains positive with strong analyst support (62.5% buy rating) and a consensus price target of $234.47, implying ~14% upside. Key risks include reliance on new drug launches to offset declining multiple sclerosis sales and integration challenges from acquisitions. Cash flow trends show variability, with 2026 projecting negative net cash flow due to significant investing activities.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ASML Holding NV
Founded in 1984 and based in the Netherlands, ASML is the leader in photolithography systems used in the manufacturing of semiconductors. Photolithography is the process in which a light source is used to expose circuit patterns from a photomask onto a semiconductor wafer. The latest technological advances in this segment allow chipmakers to continually increase the number of transistors on the same area of silicon, with lithography historically representing a meaningful portion of the cost of making cutting-edge chips. Chipmakers require next-generation EUV lithography tools from ASML to continue past the 5-nanometer process node. ASML's products are used at every major semiconductor manufacturer, including Intel, Samsung, and TSMC.
Read more on ASML →About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →
